NCT06420791

Brief Summary

Background: This study aims to investigate the correlation between cirrhosis and hepatocellular carcinoma (HCC) recurrence after Liver Transplantation. Methods: The study retrospectively collected data enrolled from 519 HCC patients who underwent liver transplantation from two center(the First Affiliated Hospital, Zhejiang University School of Medicine and Shulan (Hangzhou) Hospital, January 2015 to December 2020), Based on important variables, 1:3 propensity score matching (PSM) were performed respectively.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 28, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 3, 2024

Completed
3 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 6, 2024

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

May 14, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 20, 2024

Completed
Last Updated

May 20, 2024

Status Verified

May 1, 2024

Enrollment Period

2 months

First QC Date

May 14, 2024

Last Update Submit

May 14, 2024

Conditions

Hepatocellular CarcinomaCirrhosis

Outcome Measures

Primary Outcomes (1)

  • The overall survival rate was evaluated by follow-up investigation and outpatient review

    2-5 years

Secondary Outcomes (1)

  • The tumor-free survival rate was evaluated by follow-up investigation and outpatient review

    2-5 years

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Previously registered liver transplant recipients

You may qualify if:

  • The patients undergoing liver transplantation for HCC from January 2015 to December 2020.

You may not qualify if:

  • Re-transplantation or combined liver-kidney transplantation; incomplete laboratory or clinical data; death within 90 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhejiang University school of Medicine

Hangzhou, Zhejiang, 310000, China

Location

MeSH Terms

Conditions

Carcinoma, HepatocellularFibrosis

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator, Clinical Professor,PHD,MD

Study Record Dates

First Submitted

May 14, 2024

First Posted

May 20, 2024

Study Start

February 28, 2024

Primary Completion

May 3, 2024

Study Completion

May 6, 2024

Last Updated

May 20, 2024

Record last verified: 2024-05

Locations

CN(1)